natgillin/translations-raw huggingface dataset:
However, because sitagliptin is primarily renally eliminated, severe hepatic impairment is not expected to affect the pharmacokinetics of sitagliptin. 
Ker pa se sitagliptin primarno izloča skozi ledvice, ne pričakujemo, da bi huda okvara jeter vplivala na farmakokinetiko sitagliptina.
After a median follow up of 3 years, sitagliptin, when added to usual care, did not increase the risk of major adverse cardiovascular events or the risk of hospitalisation for heart failure compared to usual care without sitagliptin in patients with type 2 diabetes (see Table 5). 
Po 3 letih spremljanja (mediana) sitagliptin pri bolnikih s sladkorno boleznijo tipa 2, dodan običajnemu zdravljenju, ni povečal tveganja za pomembne neželene srčno-žilne dogodke ali tveganja za hospitalizacijo zaradi srčnega popuščanja v primerjavi z bolniki, ki so prejemali običajno zdravljenje brez sitagliptina (glejte preglednico 5).
If you stop taking Steglujan 
Če ste prenehali jemati zdravilo Steglujan
Because renal function abnormalities can occur after initiating ertugliflozin, and sitagliptin is known to be substantially excreted by the kidneys, renal function should be assessed more frequently in elderly patients. 
Ker se po uvedbi ertugliflozina lahko pojavijo nepravilnosti delovanja ledvic, sitagliptin pa se v veliki meri izloča skozi ledvice, je pri starejših bolnikih potrebno pogosteje oceniti delovanje ledvic.
• Steglujan can be used instead of taking both ertugliflozin and sitagliptin as separate tablets. 
• Zdravilo Steglujan se lahko uporablja namesto jemanja ertugliflozina in sitagliptina v ločenih tabletah.
Steglujan is available in Alu/PVC/PA/Alu blisters. 
Tablete zdravila Steglujan so na voljo v Alu/PVC/PA/Alu pretisnih omotih.
These included hypoglycaemia (frequency very common with the combination of sulphonylurea and metformin), influenza (common with insulin (with or without metformin)), nausea and vomiting (common with metformin), flatulence (common with metformin or pioglitazone), constipation (common with the combination of sulphonylurea and metformin), peripheral oedema (common with pioglitazone or the combination of pioglitazone and metformin), somnolence and diarrhoea (uncommon with metformin), and dry mouth (uncommon with insulin (with or without metformin)). 
Ti so vključevali hipoglikemijo (pogostnost - zelo pogosta v kombinaciji s sulfonilsečnino in metforminom), gripo (pogostnost - pogosta z insulinom (z ali brez metformina)), navzeo in bruhanje (pogostnost - pogosta z metforminom), flatulenco (pogostnost - pogosta z metforminom ali pioglitazonom), konstipacijo (pogostnost - pogosta v kombinaciji s sulfonilsečnino in metforminom), periferni edem (pogostnost - pogosta s pioglitazonom ali v kombinaciji s pioglitazonom in metforminom), zaspanost in diarejo (pogostnost - občasna z metforminom) in suha usta (pogostnostobčasna z insulinom (z ali brez metformina)).
Taking this medicine in combination with insulin or medicines that increase insulin release from the pancreas can cause blood sugar levels to drop too low (hypoglycaemia), which may cause symptoms such as shaking, sweating or changes in vision and may affect your ability to drive and use machines. 
Jemanje tega zdravila v kombinaciji z insulinom ali zdravili, ki povečajo izločanje insulina iz trebušne slinavke, lahko povzroči preveliko znižanje krvnega sladkorja (hipoglikemijo), kar lahko povzroči simptome, kot so tresenje, potenje ali sprememba vida, ter lahko poslabša sposobnost upravljanja vozil in strojev.
In the event of an overdose with Steglujan, employ the usual supportive measures (e.g., remove unabsorbed material from the gastrointestinal tract, employ clinical monitoring including obtaining an electrocardiogram, and institute supportive treatment) as dictated by the patient's clinical status. 
V primeru prevelikega odmerjanja zdravila Steglujan je treba uporabiti običajne podporne ukrepe (npr. odstraniti neabsorbirano vsebino iz prebavil, uvesti klinični nadzor, vključno z elektrokardiogramom, in podporno zdravljenje), kot narekuje bolnikovo klinično stanje.
• Steglujan lowers blood sugar levels in adult patients (aged 18 years and older) with type 2 
• Zdravilo Steglujan znižuje vrednosti krvnega sladkorja pri odraslih bolnikih (starih 18 let ali več) s sladkorno boleznijo tipa 2.
Before initiating Steglujan, volume status should be assessed and corrected if indicated. 
Pred uvedbo zdravila Steglujan je treba oceniti volumsko stanje (volemijo) in ga korigirati, če je potrebno.
Patients [N (%)] with HbA1c < 7% 66 (26.4) Body weight (kg) 
Bolniki [n (%)] s HbA1c < 7 % 66 (26,4) Telesna masa (kg)
In vitro transport studies showed that sitagliptin is a substrate for P-gp and OAT3. 
Študije transporta in vitro so pokazale, da je sitagliptin substrat za p-glikoprotein in OAT3.
Additional adverse experiences reported regardless of causal relationship to medication that occurred more frequently in patients treated with sitagliptin (not reaching the 5% level, but occurring with an incidence of > 0.5% higher with sitagliptin than that in the control group) included osteoarthritis and pain in extremity. 
Dodatna neželena učinka, o katerima so poročali ne glede na vzročno povezanost z zdravilom in ki sta se pojavila pogosteje pri bolnikih, zdravljenih s sitagliptinom (nista dosegala 5 % pojavnosti, vendar z > 0,5 % višjo pojavnostjo pri sitagliptinu kot v kontrolni skupini), sta bila osteoartritis in bolečina v okončinah.
In patients where DKA is suspected or diagnosed, treatment with Steglujan should be discontinued immediately. 
Pri bolnikih s sumom na DKA ali z diagnosticirano DKA je treba zdravljenje z zdravilom Steglujan takoj ukiniti.
C]sitagliptin oral dose, approximately 16% of the radioactivity was excreted as metabolites of sitagliptin. 
C]sitagliptina se je približno 16 % radioaktivnosti izločilo v obliki presnovkov sitagliptina.
The study population included 2,004 patients ≥ 75 years of age and 3,324 patients with renal impairment (eGFR < 60 ml/min/1.73 m 
Študijska populacija je vključevala 2.004 bolnike, stare ≥ 75 let, in 3.324 bolnikov z okvaro ledvic (eGFR < 60 ml/min/1,73 m
Other medicines and Steglujan 
Druga zdravila in zdravilo Steglujan
• interstitial lung disease 
• intersticijska pljučna bolezen,
No drug interactions studies have been performed with Steglujan and other medicinal products; however, such studies have been conducted with the individual active substances. 
Študij medsebojnega delovanja z zdravilom Steglujan in drugimi zdravili niso izvedli; so pa take študije izvedli s posameznima učinkovinama.
Hypoglycaemia has been reported in combination with sulphonylurea (4.7%-13.8%) and insulin (9.6%) (see section 4.4). 
O hipoglikemiji so poročali pri kombinaciji s sulfonilsečnino (4,7 % - 13,8 %) in z insulinom (9,6 %) (glejte poglavje 4.4).
The effects of a high-fat meal on the pharmacokinetics of ertugliflozin and sitagliptin when administered as Steglujan tablets are comparable to those reported for the individual tablets. 
Vplivi obroka z visoko vsebnostjo maščob na farmakokinetiko ertugliflozina in sitagliptina v obliki tablet zdravila Steglujan so bili podobni tistim, o katerih so poročali za posamezne tablete.
In vitro data suggest that sitagliptin does not inhibit or induce CYP450 isoenzymes. 
Podatki in vitro kažejo, da sitagliptin ne zavira in ne inducira izoencimov CYP450.
If you notice any of the serious side effects above, stop taking this medicine and contact a doctor straight away. 
Če opazite katerega koli izmed zgoraj navedenih resnih neželenih učinkov, prenehajte jemati to zdravilo in se takoj posvetujte z zdravnikom.
Pharmacotherapeutic group: Drugs used in diabetes, combinations of oral blood glucose lowering drugs, ATC code: A10BD24. 
Farmakoterapevtska skupina: zdravila za zdravljenje diabetesa, kombinacije peroralnih antidiabetikov, oznaka ATC: A10BD24
• You need to keep following your food and exercise plan while taking Steglujan. 
• Med jemanjem zdravila Steglujan se morate še naprej držati načrta prehrane in telesne aktivnosti.
• painful urination 
• boleče uriniranje,
In Phase 1 multiple-dose studies, there were no dose-related clinical adverse reactions observed with sitagliptin with doses of up to 600 mg per day for periods of up to 10 days and 400 mg per day for periods of up to 28 days. 
V študijah večkratnih odmerkov 1. faze niso opazili od odmerka odvisnih kliničnih neželenih učinkov sitagliptina pri odmerkih do 600 mg na dan v obdobju do 10 dni in 400 mg na dan v obdobju do 28 dni.
For patients treated with ertugliflozin who are being switched to Steglujan, the dose of ertugliflozin can be maintained. 
Pri bolnikih, zdravljenih z ertugliflozinom, ki preidejo na zdravilo Steglujan, je mogoče odmerek ertugliflozina ohraniti.
The activity of GLP-1 and GIP is limited by the DPP-4 enzyme, which rapidly hydrolyses the incretin hormones to produce inactive products. 
Aktivnost GLP-1 in GIP je omejena z encimom DPP-4, ki inkretine hitro hidrolizira do neaktivnih oblik.
Monitoring of renal function is recommended as follows: - Prior to Steglujan initiation and periodically during treatment (see section 4.2). 
Delovanje ledvic je priporočljivo spremljati: - pred uvedbo zdravila Steglujan in periodično med zdravljenjem (glejte poglavje 4.2).
Steglujan has not been studied in patients with severe hepatic impairment and is not recommended for use in these patients (see section 5.2). 
Zdravila Steglujan niso preučevali pri bolnikih s hudo okvaro jeter in njegova uporaba pri teh bolnikih ni priporočljiva (glejte poglavje 5.2).
Over the course of the study, the overall estimated mean (SD) difference in HbA1c between the sitagliptin and placebo groups was 0.29% (0.01), 95% CI (-0.32, -0.27); p< 0.001. 
Med potekom študije je bila celokupna ocenjena povprečna (standardni odklon) razlika v HbA1c med skupino, ki je prejemala sitagliptin, in skupino, ki je prejemala placebo, 0,29 % (0,01), 95 % IZ (-0,32; -0,27), p < 0,001.
• bullous pemphigoid (a type of skin blister) 
• bulozni pemfigoid (tip kožnega mehurja).
Experience in New York Heart Association (NYHA) class I-II is limited, and there is no experience in clinical studies with Steglujan in NYHA class III-IV. 
Izkušenj pri razredih I in II po NYHA (New York Heart Association - NYHA) je malo, izkušenj iz kliničnih študij z zdravilom Steglujan pri razredih III in IV po NYHA pa ni.
• blood tests may show changes in the amount of red blood cells in your blood (called haemoglobin) 
• preskave krvi lahko pokažejo spremembe v številu rdečih krvnih celic v krvi (imenovanih hemoglobin),
Coadministration of sitagliptin and metformin had an additive effect on active GLP-1 concentrations. 
Sočasno jemanje sitagliptina in metformina ima aditivni učinek na koncentracijo aktivnega GLP-1.
There were no additional adverse reactions identified in these three trials that included sitagliptin relative to the three placebocontrolled studies with ertugliflozin (see below). 
V teh treh preskušanjih, ki so vključevala sitagliptin, niso ugotovili dodatnih neželenih učinkov glede na tri s placebom nadzorovane študije z ertugliflozinom (glejte spodaj).
The fixed-dose combination of ertugliflozin and sitagliptin should not be used in patients with severe renal impairment, with end-stage renal disease (ESRD), or receiving dialysis. 
Kombinacije fiksnih odmerkov ertugliflozina in sitagliptina se ne sme uporabljati pri bolnikih s hudo okvaro ledvic, končno odpovedjo ledvic (ESRD - end-stage renal disease) ali bolnikih na dializi.
However, dizziness and drowsiness have been reported with sitagliptin, which may affect your ability to drive or use machines. 
Vendar pa so pri sitagliptinu poročali o pojavu omotice in zaspanosti, ki lahko vplivata na vašo sposobnost upravljanja vozil in strojev.
C]-sitagliptin dose to healthy subjects, approximately 100% of the administered radioactivity was eliminated in faeces (13%) or urine (87%) within one week of dosing. 
C]sitagliptina zdravim osebam se je v enem tednu po prejemu odmerka približno 100 % prejete radioaktivnosti izločilo z blatom (13 %) ali urinom (87 %).
• if you are allergic to ertugliflozin or sitagliptin or any of the other ingredients of this medicine 
• če ste alergični na ertugliflozin ali sitagliptin ali katero koli sestavino tega zdravila (navedeno v poglavju 6).
Compared to normal healthy control subjects, plasma AUC of sitagliptin was increased modestly in patients with GFR ≥ 45 to < 90 mL/min. 
V primerjavi z normalnimi zdravimi kontrolnimi osebami je bila pri bolnikih z GFR ≥ 45 do < 90 ml/min plazemska AUC zmerno povečana.
General Steglujan should not be used in patients with type 1 diabetes mellitus. 
Splošno Zdravila Steglujan se ne sme uporabljati pri bolnikih s sladkorno boleznijo tipa 1.
The efficacy and safety of ertugliflozin in combination with sitagliptin have been studied in 3 multicentre, randomised, double-blind, placebo- and active comparator-controlled, Phase 3 clinical studies involving 1,985 patients with type 2 diabetes. 
Učinkovitost in varnost ertugliflozina v kombinaciji s sitagliptinom so preučevali v 3 multicentričnih, randomiziranih, dvojno slepih, s placebom ali primerjalno učinkovino nadzorovanih kliničnih študijah 3. faze, ki so vključevale 1.985 bolnikov s sladkorno boleznijo tipa 2.
Incretin hormones, including glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), are released by the intestine throughout the day, and levels are increased in response to a meal. 
Inkretini, med katere spadata glukagonu podobni peptid 1 (GLP-1glucagon-like peptide-1) in od glukoze odvisni insulinotropni polipeptid (GIP - glucose-dependent insulinotropic polypeptide), se izločajo iz črevesja ves dan, njihova količina pa se po jedi poveča.
Interaction studies conducted in patients with type 2 diabetes or healthy volunteers suggest that metformin and ciclosporin had no clinically relevant effect on the pharmacokinetics of sitagliptin. 
Študije medsebojnega delovanja, ki so jih izvedli pri bolnikih s sladkorno boleznijo tipa 2 ali zdravih prostovoljcih kažejo na to, da metformin in ciklosporin nista imela klinično pomembnega učinka na farmakokinetiko sitagliptina.
What Steglujan is and what it is used for 
Kaj je zdravilo Steglujan in za kaj ga uporabljamo
EU/1/18/1266/007 (14 film-coated tablets) EU/1/18/1266/008 (28 film-coated tablets) EU/1/18/1266/009 (30 film-coated tablets) EU/1/18/1266/010 (30x1 film-coated tablets) EU/1/18/1266/011 (84 film-coated tablets) EU/1/18/1266/012 (90 film-coated tablets) EU/1/18/1266/014 (98 film-coated tablets) 
EU/1/18/1266/007 (14 filmsko obloženih tablet) EU/1/18/1266/008 (28 filmsko obloženih tablet) EU/1/18/1266/009 (30 filmsko obloženih tablet) EU/1/18/1266/010 (30 x 1 filmsko obložena tableta) EU/1/18/1266/011 (84 filmsko obloženih tablet) EU/1/18/1266/012 (90 filmsko obloženih tablet ) EU/1/18/1266/014 (98 filmsko obloženih tablet)
Effects of sitagliptin on other medicinal products 
Vpliv sitagliptina na druga zdravila
Patients 65 years and older treated with ertugliflozin, had a higher incidence of adverse reactions related to volume depletion compared to younger patients. 
Pri bolnikih, starih 65 let ali več, zdravljenih z ertugliflozinom, je bila pojavnost neželenih učinkov, povezanih s hipovolemijo, večja kot pri mlajših bolnikih.
EU/1/18/1266/001 (14 film-coated tablets) EU/1/18/1266/002 (28 film-coated tablets) EU/1/18/1266/003 (30 film-coated tablets) EU/1/18/1266/004 (30x1 film-coated tablets) EU/1/18/1266/005 (84 film-coated tablets) EU/1/18/1266/006 (90 film-coated tablets) EU/1/18/1266/013 (98 film-coated tablets) 
EU/1/18/1266/001 (14 filmsko obloženih tablet) EU/1/18/1266/002 (28 filmsko obloženih tablet) EU/1/18/1266/003 (30 filmsko obloženih tablet) EU/1/18/1266/004 (30 x 1 filmsko obložena tableta) EU/1/18/1266/005 (84 filmsko obloženih tablet) EU/1/18/1266/006 (90 filmsko obloženih tablet) EU/1/18/1266/013 (98 filmsko obloženih tablet)
In case of conditions that may lead to fluid loss (e.g., gastrointestinal illness), careful monitoring of volume status (e.g., physical examination, blood pressure measurements, laboratory tests including haematocrit) and electrolytes is recommended for patients receiving Steglujan. 
V primeru stanj, ki lahko povzročijo izgubo tekočine (npr. bolezni prebavil), se pri bolnikih, ki prejemajo zdravilo Steglujan, priporoča skrbno spremljanje volumskega stanja (npr. s fizikalnim pregledom, meritvami krvnega tlaka, laboratorijskimi preiskavami, vključno s hematokritom) in elektrolitov.
• flu 
• gripa,
Therefore, Steglujan should not be used during pregnancy. 
Zdravila Steglujan se zato med nosečnostjo ne sme uporabljati.
• Sitagliptin belongs to a group of medicines called DPP-4 (dipeptidyl peptidase-4) inhibitors. 
• Sitagliptin spada v skupino zdravil, imenovanih zaviralci DPP-4 (dipeptidil-peptidaze 4).
This medicine has no or negligible influence on the ability to drive and use machines. 
Zdravilo Steglujan nima vpliva ali ima zanemarljiv vpliv na sposobnost vožnje in upravljanja strojev.
Patients [n (%)] with HbA1c < 7% Body Weight (kg) 
Bolniki [n (%)] s HbA1c < 7 % Telesna masa (kg)
In a clinical study sitagliptin had a small effect on plasma digoxin concentrations indicating that sitagliptin may be a mild inhibitor of P-gp. 
V klinični študiji je sitagliptin imel majhen učinek na koncentracije digoksina v plazmi, kar kaže, da je sitagliptin lahko blagi zaviralec p-glikoproteina.
Steglujan is indicated in adults aged 18 years and older with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control: 
Zdravilo Steglujan je indicirano pri odraslih, starih 18 let ali več, s sladkorno boleznijo tipa 2 kot dodatek k dieti in telesni aktivnosti za izboljšanje urejenosti glikemije:
• in patients already being treated with the combination of ertugliflozin and sitagliptin as separate tablets. 
• pri bolnikih, ki že prejemajo kombinacijo ertugliflozina in sitagliptina v ločenih tabletah.
How to store Steglujan 6. 
Kako jemati zdravilo Steglujan 4.
• The active substances are ertugliflozin and sitagliptin. 
• Učinkovini sta ertugliflozin in sitagliptin.
Therefore, symptomatic hypotension may occur after initiating Steglujan (see section 4.8), particularly in patients with impaired renal function (eGFR less than 60 ml/min/1.73 m2 or CrCl less than 
Po uvedbi zdravila Steglujan se zato lahko pojavi simptomatska hipotenzija (glejte poglavje 4.8), zlasti pri bolnikih z okvarjenim delovanjem ledvic (eGFR manj kot 60 ml/min/1,73 m ali CrCl manj kot
In the intention-to-treat population, among patients who were using insulin and/or a sulphonylurea at baseline, the incidence of severe hypoglycaemia was 2.7% in sitagliptin-treated patients and 2.5% in placebo-treated patients; among patients who were not using insulin and/or a sulphonylurea at baseline, the incidence of severe hypoglycaemia was 1.0% in sitagliptin-treated patients and 0.7% in placebo-treated patients. 
V populaciji z namenom zdravljenja je bila med bolniki, ki so v izhodišču uporabljali insulin in/ali sulfonilsečnino, pojavnost hude hipoglikemije 2,7 % med tistimi, ki so prejemali sitagliptin, in 2,5 % med tistimi, ki so prejemali placebo; med bolniki, ki v izhodišču niso prejemali insulina in/ali sulfonilsečnine, je bila pojavnost hude hipoglikemije 1,0 % med bolniki, ki so prejemali sitagliptin, in 0,7 % med tistimi, ki so prejemali placebo.
Administration of Steglujan with food decreased ertugliflozin Cmax by 29% and had no meaningful effect on ertugliflozin AUCinf, or on sitagliptin AUCinf and Cmax. 
Uporaba zdravila Steglujan s hrano je zmanjšala Cmax ertugliflozina za 29 % in ni pomembno vplivala na AUCinf ertugliflozina ter na AUCinf in Cmax sitagliptina.
Post-marketing reports of serious hypersensitivity reactions in patients treated with sitagliptin have been reported (see section 4.8). 
V obdobju trženja zdravila so poročali o resnih preobčutljivostnih reakcijah pri bolnikih, ki so bili zdravljeni s sitagliptinom (glejte poglavje 4.8).
Steglujan combines two antihyperglycaemic agents with complementary mechanisms of action to improve glycaemic control in patients with type 2 diabetes: ertugliflozin, a SGLT2 inhibitor, and sitagliptin phosphate, a DPP-4 inhibitor. 
Zdravilo Steglujan je kombinacija dveh antihiperglikemičnih učinkovin s komplementarnima mehanizmoma delovanja, namenjenih izboljšanju urejenosti glikemije pri bolnikih s sladkorno boleznijo tipa 2: ertugliflozina, zaviralca SGLT2, in sitagliptinijevega fosfata, zaviralca dipeptidil-peptidaze 4 (DPP-4).
Before initiating Steglujan, factors in the patient history that may predispose to ketoacidosis should be considered. 
Pred uvedbo zdravila Steglujan je treba glede na bolnikovo anamnezo upoštevati dejavnike, ki bi lahko povečali nagnjenost h ketoacidozi.
What Steglujan is Steglujan contains two active substances, ertugliflozin and sitagliptin. 
Kaj je zdravilo Steglujan Zdravilo Steglujan vsebuje dve različni učinkovini, ertugliflozin in sitagliptin.
In patients tolerating the starting dose, the dose may be increased to 15 mg ertugliflozin/100 mg sitagliptin, once daily, if additional glycaemic control is needed. 
Pri bolnikih, ki prenašajo začetni odmerek, se odmerek lahko poveča na 15 mg ertugliflozina/100 mg sitagliptina enkrat na dan, če je potrebno dodatno urejanje glikemije.
Hypromellose (E464) Hydroxypropyl cellulose (E463) Titanium dioxide (E171) Iron oxide red (E172) Iron oxide yellow (E172) Iron oxide black (E172) Carnauba wax (E903) 
Obloga tablete hipromeloza (E464) hidroksipropilceluloza (E463) titanov dioksid (E171) rdeči železov oksid (E172) rumeni železov oksid (E172) črni železov oksid (E172) karnauba vosek (E903)
In patients with type 2 diabetes with hyperglycaemia, these changes in insulin and glucagon levels lead to lower haemoglobin A1c (HbA1c) and lower fasting and post-prandial glucose concentrations. 
Pri bolnikih s sladkorno boleznijo tipa 2 s hiperglikemijo se zaradi spremembe količine insulina in glukagona zmanjša količina hemoglobina A1c (HbA1c) in zmanjša koncentracija glukoze na tešče in po obroku.
Steglujan has been shown to be bioequivalent to coadministration of corresponding doses of ertugliflozin and sitagliptin tablets. 
Pokazalo se je, da je zdravilo Steglujan bioekvivalentno sočasni uporabi ustreznih odmerkov tablet ertugliflozina in sitagliptina.
After 26-weeks of treatment, the combination of ertugliflozin 5 mg or 15 mg and sitagliptin 100 mg resulted in statistically significant reductions in systolic blood pressure (SBP) compared to sitagliptin alone (-2.8 and -3.0 mmHg for E5/S100 and E15/S100 respectively) or placebo (-4.4 and -6.4 mmHg for E5/S100 and E15/S100, respectively). 
Po 26-tedenskem zdravljenju je pri kombinaciji ertugliflozina v odmerku 5 mg ali 15 mg in sitagliptina v odmerku 100 mg prišlo do statistično značilnega znižanja sistoličnega krvnega tlaka (SBP - systolic blood pressure) v primerjavi s samim sitagliptinom (-2,8 mmHg za E5/S100 in -3,0 mmHg za E15/S100) ali v primerjavi s placebom (-4,4 mmHg za E5/S100 in -6,4 mmHg za E15/S100).
There have been post-marketing reports of bullous pemphigoid in patients taking DPP-4 inhibitors including sitagliptin. 
V obdobju trženja so pri bolnikih, ki jemljejo zaviralce DPP-4, vključno s sitagliptinom, poročali o buloznem pemfigoidu.
The recommended starting dose is 5 mg ertugliflozin/100 mg sitagliptin once daily. 
Priporočeni začetni odmerek je 5 mg ertugliflozina/100 mg sitagliptina enkrat na dan.
Due to the mechanism of action of ertugliflozin, patients taking Steglujan will test positive for glucose in their urine. 
Zaradi mehanizma delovanja ertugliflozina bodo rezultati testov glukoze v urinu pri bolnikih, ki jemljejo zdravilo Steglujan, pozitivni.
Microcrystalline cellulose (E460) Calcium hydrogen phosphate (anhydrous) Croscarmellose sodium Sodium stearyl fumarate (E487) Magnesium stearate (E470b) 
Jedro tablete mikrokristalna celuloza (E460) kalcijev hidrogenfosfat (brezvodni) premreženi natrijev karmelozat natrijev stearilfumarat (E487) magnezijev stearat (E470b)
Blood and lymphatic system disorders 
Bolezni krvi in limfatičnega sistema redki trombocitopenija